Antibiotics in the clinical pipeline as of December 2022.
- Published in:
- Journal of Antibiotics, 2023, v. 76, n. 8, p. 431, doi. 10.1038/s41429-023-00629-8
- By:
- Publication type:
- Article
Works matching IS 00218820 AND DT 2023 AND VI 76 AND IP 8
Results: 5
1
2
A combination strategy of a semisynthetic macrolide, 5-O-mycaminosyltylonolide with polymyxin B nonapeptide for multi-drug resistance P. aeruginosa.
- Published in:
- Journal of Antibiotics, 2023, v. 76, n. 8, p. 499, doi. 10.1038/s41429-023-00628-9
- By:
- Publication type:
- Article
3
New secondary metabolites produced by Paraphoma radicina FB55 as potential antifungal agents.
- Published in:
- Journal of Antibiotics, 2023, v. 76, n. 8, p. 474, doi. 10.1038/s41429-023-00626-x
- By:
- Publication type:
- Article
4
Two non-active site residues W165 and L166 prominently influence the beta-lactam hydrolytic ability of OXA-23 beta-lactamase.
- Published in:
- Journal of Antibiotics, 2023, v. 76, n. 8, p. 489, doi. 10.1038/s41429-023-00624-z
- By:
- Publication type:
- Article
5
Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model.
- Published in:
- Journal of Antibiotics, 2023, v. 76, n. 8, p. 481, doi. 10.1038/s41429-023-00623-0
- By:
- Publication type:
- Article